• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Collaborative Approach for "ReSeq-ing" Mycobacterium tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers.

作者信息

Schito Marco, Dolinger David L

机构信息

Critical Path Institute, 1730 E River Rd, Suite 200, Tucson, Arizona, United States.

FIND, Campus Biotech, Building B2, Level 0, 9, Chemin des Mines, 1202 Geneva, Switzerland.

出版信息

EBioMedicine. 2015 Oct 9;2(10):1262-5. doi: 10.1016/j.ebiom.2015.10.008. eCollection 2015 Oct.

DOI:10.1016/j.ebiom.2015.10.008
PMID:26629499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4634747/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2398/4634747/0e87895bad09/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2398/4634747/0e87895bad09/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2398/4634747/0e87895bad09/gr1.jpg

相似文献

1
A Collaborative Approach for "ReSeq-ing" Mycobacterium tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers.一种用于结核分枝杆菌耐药性“重测序”的协作方法：药物与诊断开发者的融合。
EBioMedicine. 2015 Oct 9;2(10):1262-5. doi: 10.1016/j.ebiom.2015.10.008. eCollection 2015 Oct.
2
The "source" of drug-resistant TB outbreaks.耐多药结核病疫情的“源头”
Science. 2006 Oct 20;314(5798):419-20. doi: 10.1126/science.314.5798.419c.
3
Drug-Susceptible and Multidrug-Resistant Mycobacterium tuberculosis in a Single Patient.同一患者感染耐多药和药敏结核分枝杆菌。
Emerg Infect Dis. 2019 Nov;25(11):2120-2121. doi: 10.3201/eid2511.180638. Epub 2019 Nov 17.
4
[Mycobacterium tuberculosis with extensive resistance].具有广泛耐药性的结核分枝杆菌
Med Sci (Paris). 2007 Feb;23(2):205-9. doi: 10.1051/medsci/2007232205.
5
Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis.耐多药结核病的早期生物标志物和监管创新。
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S160-3. doi: 10.1093/cid/civ612.
6
[Molecular mechanisms of the formation of drug resistance of Mycobacterium tuberculosis (review of the literature)].[结核分枝杆菌耐药性形成的分子机制（文献综述）]
Probl Tuberk. 2001(6):48-9.
7
[Advances in chemotherapy of multidrug-resistant and rifampicin-resistant tuberculosis].[耐多药和利福平耐药结核病的化疗进展]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Apr 12;43(4):371-375. doi: 10.3760/cma.j.cn112147-20190830-00610.
8
[The problems in the chemotherapy of tuberculosis taking into account new data on its causative organism].[考虑到结核病病原体的新数据，结核病化疗中的问题]
Antibiot Khimioter. 2000;45(5):3-5.
9
Will molecular diagnosis of drug-resistant tuberculosis improve patient outcomes?耐多药结核病的分子诊断能否改善患者预后？
Int J Tuberc Lung Dis. 2012 Jan;16(1):4-5. doi: 10.5588/ijtld.11.0419.
10
Drug-resistant tuberculosis: pediatric guidelines.耐药结核病：儿科指南。
Pediatr Infect Dis J. 2011 Jun;30(6):501-5. doi: 10.1097/INF.0b013e31820b583d.

引用本文的文献

1
The Relative Positioning of Genotyping and Phenotyping for Tuberculosis Resistance Screening in Two EU National Reference Laboratories in 2023.2023年两个欧盟国家参考实验室中结核病耐药性筛查的基因分型与表型分型的相对定位
Microorganisms. 2023 Jul 14;11(7):1809. doi: 10.3390/microorganisms11071809.
2
Identification and Characterization of Mycobacterial Species Using Whole-Genome Sequences.基于全基因组序列鉴定和描述分枝杆菌菌种。
Methods Mol Biol. 2021;2314:399-457. doi: 10.1007/978-1-0716-1460-0_19.
3
Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

本文引用的文献

1
Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform.建立全球结核病相关测序数据集中平台的协作努力。
Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S141-6. doi: 10.1093/cid/civ610.
2
Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study.全基因组测序用于预测结核分枝杆菌药物敏感性和耐药性：一项回顾性队列研究。
Lancet Infect Dis. 2015 Oct;15(10):1193-1202. doi: 10.1016/S1473-3099(15)00062-6. Epub 2015 Jun 23.
3
Improving the tuberculosis drug development pipeline.
整合标准化全基因组序列分析与全球结核分枝杆菌抗生素耐药知识库。
Sci Rep. 2018 Oct 18;8(1):15382. doi: 10.1038/s41598-018-33731-1.
4
Mycobacterial biomaterials and resources for researchers.用于研究人员的分枝杆菌生物材料和资源。
Pathog Dis. 2018 Jun 1;76(4). doi: 10.1093/femspd/fty042.
改善结核病药物研发流程。
Chem Biol Drug Des. 2015 Nov;86(5):951-60. doi: 10.1111/cbdd.12549. Epub 2015 Mar 28.
4
Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis.将已发表信息整合到结核分枝杆菌耐药相关突变数据库中。
J Infect Dis. 2015 Apr 1;211 Suppl 2(Suppl 2):S50-7. doi: 10.1093/infdis/jiu816.
5
Molecular diagnostics for tuberculosis.结核病的分子诊断
Pathology. 2015 Apr;47(3):250-6. doi: 10.1097/PAT.0000000000000232.
6
Facing multi-drug resistant tuberculosis.面对多重耐药结核病。
Pulm Pharmacol Ther. 2015 Jun;32:144-8. doi: 10.1016/j.pupt.2014.04.006. Epub 2014 Apr 30.
7
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.新结核病药物方案与药物敏感性测试的一致性：行动框架。
Lancet Infect Dis. 2013 May;13(5):449-58. doi: 10.1016/S1473-3099(13)70025-2. Epub 2013 Mar 24.
8
Prospects for tuberculosis elimination.结核病消除的前景。
Annu Rev Public Health. 2013;34:271-86. doi: 10.1146/annurev-publhealth-031912-114431. Epub 2012 Dec 14.
9
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis.结核分枝杆菌突变和遗传背景对耐药性的影响。
Antimicrob Agents Chemother. 2012 Jun;56(6):3047-53. doi: 10.1128/AAC.06460-11. Epub 2012 Apr 2.